The senseless orphanage of Chagas disease

Introduction: Chagas disease is caused by the parasite Trypanosoma cruzi. Endemic in 21 American countries, there are ~7 million people infected, of which 14,000 die every year. Despite this burden, Chagas remains an orphan disease as it mainly affects poor communities with low economic and politica...

Descripción completa

Detalles Bibliográficos
Autores: Alonso Vega, Cristina, Losada, Irene, Pinazo, Maria-Jesus, Sancho Mas, Javier, Gascón i Brustenga, Joaquim, Alonso Padilla, Julio
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2019
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/150477
Acceso en línea:https://hdl.handle.net/2445/150477
Access Level:acceso abierto
Palabra clave:Malaltia de Chagas
Tripanosoma
Chagas' disease
Trypanosoma
id ES_49efac70e9a3496f1a4d3a88e8dfebd4
oai_identifier_str oai:diposit.ub.edu:2445/150477
network_acronym_str ES
network_name_str España
repository_id_str
spelling The senseless orphanage of Chagas diseaseAlonso Vega, CristinaLosada, IrenePinazo, Maria-JesusSancho Mas, JavierGascón i Brustenga, JoaquimAlonso Padilla, JulioMalaltia de ChagasTripanosomaChagas' diseaseTrypanosomaIntroduction: Chagas disease is caused by the parasite Trypanosoma cruzi. Endemic in 21 American countries, there are ~7 million people infected, of which 14,000 die every year. Despite this burden, Chagas remains an orphan disease as it mainly affects poor communities with low economic and political power. Areas covered: There are two drugs available to treat the infection, but both have safety and efficacy issues. Investment in new treatments and other control measures has been historically neglected. This trend is changing and there are novel perspectives to put an end to this senseless orphanage. Research and development agenda of new therapies, diagnostic tools and biomarkers have moved forward during the last decade; and patients associations have been active in promoting awareness of the disease all along. Besides, the WHO recently declared April 14th as the ‘World Chagas disease day’, which will increase the visibility of the disease and attract attention internationally. Expert opinion: Efforts must focus on the prevention of new infections, but also in the management of the millions already chronically infected. This will require an integral approach where increasing the number of trained health workers and generalizing access to diagnosis and treatment will be fundamental.Taylor & Francis, Ltd.2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/150477Articles publicats en revistes (ISGlobal)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: http://dx.doi.org/10.1080/21678707.2019.1701432Expert Opinion on Orphan Drugs, 2019, vol. 7, num. 12, p. 535-545http://dx.doi.org/10.1080/21678707.2019.1701432(c) Taylor & Francis, Ltd., 2019info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1504772026-05-27T06:46:51Z
dc.title.none.fl_str_mv The senseless orphanage of Chagas disease
title The senseless orphanage of Chagas disease
spellingShingle The senseless orphanage of Chagas disease
Alonso Vega, Cristina
Malaltia de Chagas
Tripanosoma
Chagas' disease
Trypanosoma
title_short The senseless orphanage of Chagas disease
title_full The senseless orphanage of Chagas disease
title_fullStr The senseless orphanage of Chagas disease
title_full_unstemmed The senseless orphanage of Chagas disease
title_sort The senseless orphanage of Chagas disease
dc.creator.none.fl_str_mv Alonso Vega, Cristina
Losada, Irene
Pinazo, Maria-Jesus
Sancho Mas, Javier
Gascón i Brustenga, Joaquim
Alonso Padilla, Julio
author Alonso Vega, Cristina
author_facet Alonso Vega, Cristina
Losada, Irene
Pinazo, Maria-Jesus
Sancho Mas, Javier
Gascón i Brustenga, Joaquim
Alonso Padilla, Julio
author_role author
author2 Losada, Irene
Pinazo, Maria-Jesus
Sancho Mas, Javier
Gascón i Brustenga, Joaquim
Alonso Padilla, Julio
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Malaltia de Chagas
Tripanosoma
Chagas' disease
Trypanosoma
topic Malaltia de Chagas
Tripanosoma
Chagas' disease
Trypanosoma
description Introduction: Chagas disease is caused by the parasite Trypanosoma cruzi. Endemic in 21 American countries, there are ~7 million people infected, of which 14,000 die every year. Despite this burden, Chagas remains an orphan disease as it mainly affects poor communities with low economic and political power. Areas covered: There are two drugs available to treat the infection, but both have safety and efficacy issues. Investment in new treatments and other control measures has been historically neglected. This trend is changing and there are novel perspectives to put an end to this senseless orphanage. Research and development agenda of new therapies, diagnostic tools and biomarkers have moved forward during the last decade; and patients associations have been active in promoting awareness of the disease all along. Besides, the WHO recently declared April 14th as the ‘World Chagas disease day’, which will increase the visibility of the disease and attract attention internationally. Expert opinion: Efforts must focus on the prevention of new infections, but also in the management of the millions already chronically infected. This will require an integral approach where increasing the number of trained health workers and generalizing access to diagnosis and treatment will be fundamental.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/150477
url https://hdl.handle.net/2445/150477
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: http://dx.doi.org/10.1080/21678707.2019.1701432
Expert Opinion on Orphan Drugs, 2019, vol. 7, num. 12, p. 535-545
http://dx.doi.org/10.1080/21678707.2019.1701432
dc.rights.none.fl_str_mv (c) Taylor & Francis, Ltd., 2019
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Taylor & Francis, Ltd., 2019
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis, Ltd.
publisher.none.fl_str_mv Taylor & Francis, Ltd.
dc.source.none.fl_str_mv Articles publicats en revistes (ISGlobal)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407454906810368
score 15.301603

Similares en LA Referencia